FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to formula I compound:
or its pharmaceutically acceptable salt, or stereoisomer; where each of R1, R2 and R3 is independently selected from the group, consisting of -H, -D, -CI, -F and -C1-C3alkyl; each of W1 and W2 represents NR, or W1 and W2 together can form imidazolidine or piperazine group; each a, b, c and d independently represent -H, -D, -CH3 or -C(O)OR, or two of a, b, c and d, together with single carbon atom, which they are bound to, can form cycloalkyl; each n, o, p and q independently equals 0 or 1; each L independently represent -O-,-S-,-S-S-,
or 
m equals 0 or 1; each R6 independently represents H or C1-C6alkyl; each R7 independently represents H or non-branched or branched C1-C10alkyl; each Z independently represents
or 
each r independently equals 2, 3 or 7; each s independently equals 3, 5 or 6; t equals 1; each v independently equals 1 or 2; each of R4 and R5 independently represents hydrogen, deuterium or -C1-C4alkyl; and each R independently represents -H or -C1-C3alkyl.
EFFECT: compounds can be used for treatment or prevention of metabolic disorder.
38 cl, 13 ex
